(Source: Bristol-Myers Squibb Company) BMS-663068 is the first investigational antiretroviral designed to prevent HIV attachment to and entry into CD4+ T cells FDA Breakthrough Designation recognizes the need for new therapies for heavily treatment-experienced HIV-1 patients and may expedite the development and review of BMS-663068 Designation granted for investigational agent BMS-663068 in combination with other antiretroviral agents for treatment of HIV-1 in heavily treatment-experienced patients Dateline: "The Breakthrough Designation recognizes the unmet need for novel therapies for this growing group of heavily treatment-experienced patients, and is evidence of Bristol-Myers...
↧